Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GW 181771

Drug Profile

GW 181771

Alternative Names: GI 181771; GSKI-181771X; GW-181771

Latest Information Update: 11 May 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Class Obesity therapies
  • Mechanism of Action Cholecystokinin A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Bulimia nervosa; Obesity

Most Recent Events

  • 11 May 2017 Discontinued - Phase-II for Bulimia nervosa in USA (unspecified route)
  • 26 Apr 2017 GlaxoSmithKline terminates a phase II trial in Bulimia nervosa in USA as the drug expired before the trial was completed (NCT00600743)
  • 21 Apr 2005 Discontinued - Phase-II for Obesity in United Kingdom (unspecified route)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top